New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
06:12 EDTAAPL, INTC, MSFT, THLD, AMGN, GSK, TM, NSANY, HMC, VLKAY, FIATY, F, GMOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: As U.S. companies hold near record amounts of cash, many are surprisingly cash poor at home. That means there could be unseen limits on their ability to pay dividends and buy back shares, the Wall Street Journal reports...In November, U.S. sales of cars and light trucks were the strongest in over four years, jumping 15% to 1.14M compared with a year ago. The seasonally adjusted annualized sales rate was 15.5M, the highest since January 2008, according to Autodata, the Wall Street Journal reports...REUTERS: Fed bankers appear satisfied with their latest monetary stimulus, but there's some disagreement over how strongly to continue purchasing bonds. Boston Fed President Rosengren said there was a "strong case" for the Fed to stay the course, while St. Louis Fed President Bullard said they shouldn’t replace its expiring 'Operation Twist' program on a dollar-for-dollar basis, Reuters reports...U.S. rail and trucking companies are making big investments on both sides of the border with Mexico to capitalize on booming trade between the two countries, Reuters reports...BLOOMBERG: Four experimental cancer treatments that may one day help gravely ill children are facing review by U.S. pediatric advisers. The medicines from GlaxoSmithKline (GSK), Amgen (AMGN) Threshold (THLD) and Boehringer Ingelheim have the potential to treat children with a variety of tumors and fast-spreading leukemia, Bloomberg reports...The move by Microsoft (MSFT) and Intel (INTC) to combat Apple’s (AAPL) iPad in the $63.2B tablet market is getting off to a slow start, Bloomberg reports.
News For GM;F;FIATY;VLKAY;HMC;NSANY;TM;GSK;AMGN;THLD;MSFT;INTC;AAPL From The Last 14 Days
Check below for free stories on GM;F;FIATY;VLKAY;HMC;NSANY;TM;GSK;AMGN;THLD;MSFT;INTC;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | all recent news | >>
July 16, 2014
07:14 EDTGSKIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
07:06 EDTINTCIntel price target raised to $36 from $31 at Stifel
Stifel increased its price target on Intel after the company reported stronger than expected results for its June quarter and provided guidance for its September quarter that the firm views favorably. Stifel keeps a Buy rating on the shares.
07:01 EDTINTCIntel price target raised to $40 from $35 at Deutsche Bank
Subscribe for More Information
07:00 EDTINTCIntel price target raised to $40 from $35 at Credit Suisse
Subscribe for More Information
06:55 EDTAAPLSurvey shows Samsung losing smartphone ground, Reuters says
Subscribe for More Information
06:38 EDTAAPLApple price target raised to $107 on enterprise opportunity at Goldman
Subscribe for More Information
06:35 EDTHMCAcura aims for boost from new TLX vehicle in U.S., Bloomberg says
Honda’s U.S. senior vice president who leads the Acura brand, Mike Accavitti, said the brand has scrambled to raise U.S. deliveries amid competition from larger luxury vehicles and expects it to experience quicker growth starting in August with the arrival of the new mid-size TLX, according to Bloomberg, citing comments from Accavitti. Reference Link
06:31 EDTGMDocuments show GM hid defect from regulators, NY Times reports
Documents indicate that GM knew at least three fatal crashes were caused by its faulty ignition switches, but failed to tell regulators that when asked about the cause of the accidents, according to The New York Times. Reference Link
06:29 EDTGMSenators turn scrutiny towards GM General Counsel, WSJ reports
Subscribe for More Information
06:24 EDTMSFTMicrosoft aims to reduce 1K jobs in Finland, Reuters says
Subscribe for More Information
06:20 EDTAAPLDRAM chip prices likely to increase 10% in July, DigiTimes reports
Subscribe for More Information
06:19 EDTGM, FIATY, FFord, GM, Chrysler not interested in Tesla patents, Detroit News says
Ford (F), General Motors (GM), and Chrysler (FIATY) either have little interest in Tesla's (TSLA) EV patents or the companies are not sharing their plans, reports the Detroit News. Reference Link
06:18 EDTAAPLApple's iPhone orders to benefit Taiwan component maker revenue, DigiTimes says
Subscribe for More Information
06:17 EDTAAPLApple initiated with a Buy at Citigroup
Citigroup believes consensus expectations are underappreciating the upgrade potential of Apple’s installed base. Citi believes Street estimates for 2015 and 2016 are too low and started shares of Apple with a Buy rating and $110 price target.
06:14 EDTMSFT, AAPLABI Research: More than 2B smartphones to ship in 2018, DigiTimes says
Subscribe for More Information
06:08 EDTINTCIntel moving 360 employees from Israel to Ireland, Globes reports
Subscribe for More Information
06:06 EDTINTCIntel upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
06:04 EDTINTCIntel upgraded to Buy from Neutral at UBS
Subscribe for More Information
05:55 EDTINTCIntel price target raised to $37 from $31 at Piper Jaffray
Piper Jaffray raised its price target for Intel shares to $37 saying the company's momentum continues following its Q2 report. Piper keeps an Overweight rating on the stock.
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use